BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Reportedly from literature, at least one third of patients who initially respond to tyrosine kinase inhibitor (TKI) treatment relapsed due to the BCR::ABL1 kinase activity independence of primitive chronic myeloid leukemia cells (1–3).